Brukinsa 80 mg Capsule

Description

Brukinsa 80 mg Capsule contains zanubrutinib, a targeted anticancer medicine classified as a Bruton’s tyrosine kinase (BTK) inhibitor. It is used in the treatment of certain B-cell malignancies, a group of blood cancers that affect white blood cells. By targeting specific signaling pathways that help cancer cells grow and survive, Brukinsa helps slow or reduce the progression of these conditions when used as prescribed by a qualified healthcare professional. Brukinsa is commonly used in adults diagnosed with conditions such as mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL), depending on regulatory approvals and physician guidance. It is taken orally in capsule form and is generally prescribed as part of a long-term treatment plan under medical supervision. Because targeted therapies can influence

Benefits

• Targets BTK signaling, a key pathway involved in certain B-cell cancers

• Oral capsule formulation that may allow outpatient treatment

• Designed to provide selective BTK inhibition, which may help reduce disease progression in certain patients

• May be used in patients who have received prior therapies depending on clinical guidance

• Part of modern targeted therapy approaches used in hematologic oncology

Indications and Usage

Brukinsa (zanubrutinib) may be prescribed for adults for conditions such as:

• Mantle Cell Lymphoma (MCL) in patients who have received prior therapy

• Waldenström’s Macroglobulinemia (WM)

• Chronic Lymphocytic Leukemia (CLL)

• Small Lymphocytic Lymphoma (SLL)

• Other approved B-cell malignancies, depending on regional regulatory approvals

Use is determined by an oncologist based on diagnosis, treatment history, and clinical guidelines.

How it Works

Zanubrutinib works by selectively inhibiting Bruton’s tyrosine kinase (BTK), an enzyme that plays a crucial role in the signaling pathway of B-lymphocytes, a type of white blood cell involved in immune function. In certain blood cancers, abnormal B-cells rely on BTK signaling to survive and multiply.

By blocking BTK activity, zanubrutinib interferes with these signals, which can reduce the growth and survival of malignant B-cells. This targeted approach focuses on molecular pathways associated with the disease, helping slow disease progression in some patients when used as prescribed and monitored by a healthcare professional.

Dosage & Administration

• Brukinsa capsules are taken orally, usually once or twice daily depending on the prescribed regimen.

• Capsules should be swallowed whole with water.

• It may be taken with or without food, unless directed otherwise by a healthcare professional.

• Do not crush, chew, or open capsules.

• If a dose is missed, follow the guidance provided by the prescribing physician.

• Treatment schedules and duration are determined by the oncologist based on clinical response and tolerance.

Side Effects

Common side effects

• Decreased white blood cell counts

• Upper respiratory infections

• Bruising or bleeding

• Rash

• Diarrhea

• Fatigue

• Muscle or joint pain

Serious side effects

• Severe infections

• Major bleeding events

• Low blood cell counts (neutropenia, thrombocytopenia, anemia)

• Heart rhythm problems such as atrial fibrillation

• Secondary malignancies including skin cancers

Patients should report unusual symptoms to their healthcare provider promptly.

Warning and Precaution

• Risk of serious infections during treatment

• Increased risk of bleeding or hemorrhage

• Possible low blood cell counts, requiring routine monitoring

• Potential heart rhythm disturbances, including atrial fibrillation

• Risk of secondary cancers, particularly skin cancers

• Inform the doctor before surgery or dental procedures

• Pregnancy and breastfeeding considerations should be discussed with a healthcare provider

• Use caution in patients taking blood thinners or antiplatelet medicines

Patient Guidance

• Take the medicine exactly as prescribed by your oncologist

• Attend regular blood tests and follow-up appointments

• Report signs of infection, unusual bleeding, or heart symptoms

• Avoid self-adjusting doses without medical advice

• Inform healthcare providers about all medicines, supplements, and herbal products you use

• Use sun protection due to potential skin cancer risk

• Store the medicine according to recommended conditions

Clinical Trial & Approvals

Zanubrutinib has been evaluated in multiple clinical trials studying its effectiveness in B-cell malignancies, including mantle cell lymphoma, Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia. Regulatory approvals have been granted in several regions, including by agencies such as the U.S. FDA and other international regulators, for specific indications based on clinical study outcomes and safety evaluations.

References

• U.S. Food and Drug Administration (FDA).
  Brukinsa (zanubrutinib) Prescribing Information.
  https://www.accessdata.fda.gov

• European Medicines Agency (EMA).
  Brukinsa (zanubrutinib) – European Public Assessment Report.
  https://www.ema.europa.eu

• National Cancer Institute (NCI).
  Zanubrutinib – Drug Information Summary.
  https://www.cancer.gov

• Drugs.com.
  Zanubrutinib: Uses, Dosage, Side Effects, Warnings.
  https://www.drugs.com

• MedlinePlus – U.S. National Library of Medicine.
  Zanubrutinib Drug Information.
  https://medlineplus.gov

• ClinicalTrials.gov.
  Studies evaluating Zanubrutinib in B-cell malignancies.
  https://clinicaltrials.gov

• BeiGene Ltd.
  Brukinsa (zanubrutinib) Official Product Information.
  https://www.brukinsa.com

• National Comprehensive Cancer Network (NCCN).
  NCCN Guidelines for B-Cell Lymphomas and Chronic Lymphocytic Leukemia.